These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 26643174)

  • 1. PTH-Induced Osteoblast Proliferation Requires Upregulation of the Ubiquitin-Specific Peptidase 2 (Usp2) Expression.
    Shirakawa J; Harada H; Noda M; Ezura Y
    Calcif Tissue Int; 2016 Mar; 98(3):306-15. PubMed ID: 26643174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells.
    Datta NS; Pettway GJ; Chen C; Koh AJ; McCauley LK
    J Bone Miner Res; 2007 Jul; 22(7):951-64. PubMed ID: 17501623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest.
    Datta NS; Chen C; Berry JE; McCauley LK
    J Bone Miner Res; 2005 Jun; 20(6):1051-64. PubMed ID: 15883646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid hormone increases beta-catenin levels through Smad3 in mouse osteoblastic cells.
    Tobimatsu T; Kaji H; Sowa H; Naito J; Canaff L; Hendy GN; Sugimoto T; Chihara K
    Endocrinology; 2006 May; 147(5):2583-90. PubMed ID: 16484320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parathyroid hormone induces mitogen-activated kinase phosphatase 1 in murine osteoblasts primarily through cAMP-protein kinase A signaling.
    Aghaloo TL; Pirih FQ; Shi A; Bezouglaia O; Tetradis S
    J Periodontol; 2006 Jan; 77(1):21-30. PubMed ID: 16579699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sustained RANKL response to parathyroid hormone in oncostatin M receptor-deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo.
    Walker EC; Poulton IJ; McGregor NE; Ho PW; Allan EH; Quach JM; Martin TJ; Sims NA
    J Bone Miner Res; 2012 Apr; 27(4):902-12. PubMed ID: 22190112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endogenous FGF-2 is critically important in PTH anabolic effects on bone.
    Sabbieti MG; Agas D; Xiao L; Marchetti L; Coffin JD; Doetschman T; Hurley MM
    J Cell Physiol; 2009 Apr; 219(1):143-51. PubMed ID: 19107841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of 1,25-dihydroxyvitamin D3 receptors by parathyroid hormone in osteoblastic cells: role of second messenger pathways.
    Krishnan AV; Cramer SD; Bringhurst FR; Feldman D
    Endocrinology; 1995 Feb; 136(2):705-12. PubMed ID: 7835303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3',5'-Cyclic adenosine monophosphate activation in osteoblastic cells: effects on parathyroid hormone-1 receptors and osteoblastic differentiation in vitro.
    Koh AJ; Beecher CA; Rosol TJ; McCauley LK
    Endocrinology; 1999 Jul; 140(7):3154-62. PubMed ID: 10385409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell-to-cell communication in osteoblastic networks: cell line-dependent hormonal regulation of gap junction function.
    Donahue HJ; McLeod KJ; Rubin CT; Andersen J; Grine EA; Hertzberg EL; Brink PR
    J Bone Miner Res; 1995 Jun; 10(6):881-9. PubMed ID: 7572312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a PTH regulated gene selectively induced in vivo during PTH-mediated bone formation.
    Robinson JA; Susulic V; Liu YB; Taylor C; Hardenburg J; Gironda V; Zhao W; Kharode Y; McLarney S; Bai Y; Malone DP; Murrills R; Bex F
    J Cell Biochem; 2006 Aug; 98(5):1203-20. PubMed ID: 16514668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Parathyroid hormone regulates fates of murine osteoblast precursors in vivo.
    Balani DH; Ono N; Kronenberg HM
    J Clin Invest; 2017 Sep; 127(9):3327-3338. PubMed ID: 28758904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Normal epidermal growth factor receptor signaling is dispensable for bone anabolic effects of parathyroid hormone.
    Schneider MR; Dahlhoff M; Andrukhova O; Grill J; Glösmann M; Schüler C; Weber K; Wolf E; Erben RG
    Bone; 2012 Jan; 50(1):237-44. PubMed ID: 22056328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-18 is regulated by parathyroid hormone and is required for its bone anabolic actions.
    Raggatt LJ; Qin L; Tamasi J; Jefcoat SC; Shimizu E; Selvamurugan N; Liew FY; Bevelock L; Feyen JH; Partridge NC
    J Biol Chem; 2008 Mar; 283(11):6790-8. PubMed ID: 18165223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of differentiation and transforming growth factor beta 1 on PTH/PTHrP receptor mRNA levels in MC3T3-E1 cells.
    McCauley LK; Koh AJ; Beecher CA; Cui Y; Decker JD; Franceschi RT
    J Bone Miner Res; 1995 Aug; 10(8):1243-55. PubMed ID: 8585429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Per-1 is a specific clock gene regulated by parathyroid hormone (PTH) signaling in osteoblasts and is functional for the transcriptional events induced by PTH.
    Hanyu R; Hayata T; Nagao M; Saita Y; Hemmi H; Notomi T; Nakamoto T; Schipani E; Knonenbery H; Kaneko K; Kurosawa H; Ezura Y; Noda M
    J Cell Biochem; 2011 Feb; 112(2):433-8. PubMed ID: 21268064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell cycle and apoptosis regulatory protein (CARP)-1 is expressed in osteoblasts and regulated by PTH.
    Sharma S; Mahalingam CD; Das V; Jamal S; Levi E; Rishi AK; Datta NS
    Biochem Biophys Res Commun; 2013 Jul; 436(4):607-12. PubMed ID: 23764399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of cyclin-dependent kinase 1 impairs bone formation, but does not affect the bone-anabolic effects of parathyroid hormone.
    Takahashi A; Mulati M; Saito M; Numata H; Kobayashi Y; Ochi H; Sato S; Kaldis P; Okawa A; Inose H
    J Biol Chem; 2018 Dec; 293(50):19387-19399. PubMed ID: 30366983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of osteoblast Phex expression by PTH.
    Alos N; Ecarot B
    Bone; 2005 Oct; 37(4):589-98. PubMed ID: 16084134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34.
    Miao D; He B; Jiang Y; Kobayashi T; Sorocéanu MA; Zhao J; Su H; Tong X; Amizuka N; Gupta A; Genant HK; Kronenberg HM; Goltzman D; Karaplis AC
    J Clin Invest; 2005 Sep; 115(9):2402-11. PubMed ID: 16138191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.